PURPLE BIOTECH (PPBT) Company Report

Analyst Coverage

Research analysts covering PURPLE BIOTECH.

Recent press releases and 8-K filings for PPBT.

Purple Biotech Ltd. Provides Q3 2025 Corporate Presentation Update

PPBT

New Projects/Investments

Guidance Update

Purple Biotech Ltd. reported a cash balance of $10.5 million as of September 30, 2025, which is expected to provide a financial runway into the first half of 2027.
The company's CM24 drug candidate, an aCEACAM1 antibody, demonstrated positive randomized Phase 2a results in metastatic pancreatic ductal adenocarcinoma (PDAC), showing a 19% reduction in the risk of death and a 25% reduction in the risk of progression or death.
NT219, an IRS1/2 degrader and STAT3 blocker, has shown safety and anti-tumor activity in Phase 1 and initiated a Phase 2 study in June 2025 for recurrent/metastatic head and neck cancer (R/M HNSCC).
The CAPTN-3 tri-specific antibody platform, including IM1240, has IND submission planned for mid-2026 and first-in-human (FIH) clinical trials in the second half of 2026.

Nov 19, 2025, 10:07 PM

Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update

PPBT

Earnings

New Projects/Investments

Purple Biotech reported a net loss of $1.3 million, or $0.29 per basic and diluted ADS, for the three months ended September 30, 2025.
The company's operating loss for the third quarter of 2025 was $1.4 million, representing a 35.8% decrease compared to the same period in 2024.
As of September 30, 2025, Purple Biotech had $10.5 million in cash and cash equivalents and short-term deposits, with an anticipated cash runway into the first half of 2027.
The company initiated development of IM1305, a second CAPTN-3 tri-specific antibody targeting TROP2, and achieved a manufacturing milestone for IM1240, with IND submission and study initiation for IM1240 planned for 2026.

Nov 14, 2025, 1:17 PM

Purple Biotech achieves manufacturing milestone for IM1240

PPBT

New Projects/Investments

Purple Biotech Ltd. announced on October 29, 2025, the achievement of a manufacturing milestone for IM1240, a tri-specific antibody from its CAPTN-3 platform, by establishing a commercially viable yield and validating the platform's scalability.
IM1240, the first CAPTN-3 tri-specific antibody, is advancing toward first-in-human clinical trials, with an Investigational New Drug (IND) submission planned for 2026.
The company developed a high-efficiency manufacturing and purification process for tri-specific antibodies, designed to deliver a differentiated T cell engager with a capped, cleavable polypeptide to help prevent off-tumor immune activation.

Oct 29, 2025, 11:33 AM

Purple Biotech receives Nasdaq minimum bid price notification

PPBT

Delisting/Listing Issues

Purple Biotech Ltd. (PPBT) received a Nasdaq notification on October 16, 2025, for non-compliance with the $1.00 minimum bid price rule, as its American Depositary Shares (ADSs) traded below this threshold for 30 consecutive days.
The company has 180 calendar days, until April 14, 2026, to regain compliance by achieving a closing bid price of $1.00 or more for ten consecutive business days.
This notification has no immediate effect on the company's Nasdaq listing or the trading of its ADSs.
Purple Biotech intends to monitor its ADS bid price and may consider options to cure the deficiency, including potentially changing the ratio between its ADSs and ordinary shares.

Oct 20, 2025, 8:01 PM

Purple Biotech Enters New At The Market Offering Agreement

PPBT

Purple Biotech Ltd. entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC on September 19, 2025, to offer and sell American Depositary Shares (ADSs) with an aggregate offering price of up to $2,300,000.
Each ADS under the new agreement represents 200 ordinary shares, and H.C. Wainwright & Co., LLC will receive a 3.0% placement fee on the gross sales price.
Effective September 18, 2025, the company terminated its Open Market Sale Agreement with Jefferies LLC.
Under the terminated Jefferies ATM Program, Purple Biotech sold 983,317 ADSs for aggregate gross proceeds of $7,729,691, at an average price of $7.86 per ADS.

Sep 19, 2025, 9:28 PM

Purple Biotech Presents September 2025 Corporate Update

PPBT

Product Launch

New Projects/Investments

Guidance Update

Purple Biotech reported a cash balance of $10.5 million as of September 10, 2025, providing a cash runway into the first half of 2027.
The company is progressing two first-in-class drugs in Phase 2: CM24, an aCEACAM1 antibody with positive randomized Phase 2a results for pancreatic cancer, and NT219, an IRS1/2 degrader and STAT3 blocker, which initiated a Phase 2 study in June 2025 for recurrent/metastatic Head & Neck Cancer.
Development continues for CAPTN-3, a next-generation tri-specific antibody platform, with first-in-human trials anticipated in 2026.

Sep 15, 2025, 11:20 PM

Get instant answers from SEC filings, earnings calls & more